Aptevo Therapeutics Inc

Today we're talking about the power of our platform technologies, ADAPTIR™ and ADAPTIR-FLEX™. Our Senior Director of Protein Engineering, Peter Pavlik, PhD, will chair a "Bi and Multispecific Biologics" session and present a talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform," at the Cambridge Healthcare Institute’s, Pep Talk conference, in January 2025. We're excited because the talk will showcase the speed and efficiency of our drug development capabilities. This underscores the Aptevo commitment to driving innovation in functional drug production and creating molecules that perform in the clinic the way they were designed to perform at inception. https://lnkd.in/etTNKcCe

Marvin White, President and CEO of Aptevo commenting on the promise of the Aptevo pipeline in context with the growing success of bispecifics as a category. “Bispecifics are increasing in importance across the cancer therapeutic landscape and the market is expected to grow by as much as 44% through 2030*. Fueled by their ability to engage multiple targets, bispecifics provide a technology that utilizes various mechanisms of action with an enhanced safety profile.  Aptevo’s focused yet diversified pipeline aligns with these industry trends, offering a compelling investment opportunity that may address critical therapeutic gaps,” said Marvin White, President and CEO of Aptevo. (*Grand View Research) Read more: https://lnkd.in/eb6_tSZU

Marvin White, President and CEO of Aptevo commenting on the promise of the Aptevo pipeline in context with the growing success of bispecifics as a category. “Bispecifics are increasing in importance across the cancer therapeutic landscape and the market is expected to grow by as much as 44% through 2030*. Fueled by their ability to engage multiple targets, bispecifics provide a technology that utilizes various mechanisms of action with an enhanced safety profile.  Aptevo’s focused yet diversified pipeline aligns with these industry trends, offering a compelling investment opportunity that may address critical therapeutic gaps,” said Marvin White, President and CEO of Aptevo. (*Grand View Research) Read more: https://lnkd.in/eb6_tSZU

We’re excited to share promising news from our ongoing RAINIER Phase 1b/2 trial: The first patient dosed with mipletamig achieved a 90% reduction in leukemic blasts within the first 30 days of treatment, continuing the strong efficacy trend seen in prior studies. Mipletamig is our CD3 x CD123 bispecific antibody currently being evaluated in combination with standard-of-care therapies. This multi-mechanism approach has the potential to redefine frontline AML treatment and improve patient outcomes. Favorable early safety, efficacy, tolerability, and durability of remission data have informed and guided the advancement of this trial. At Aptevo, we’re committed to bringing innovative solutions to patients battling AML and other cancers. Link to the press release to read more about the potential and the promise of mipletamig: https://lnkd.in/eUax5t5k #AptevoTherapeutics #Mipletamig #AML #OncologyInnovation #CancerResearch #Biotech

At Aptevo Therapeutics, we are committed to developing innovative solutions for patients battling acute myeloid leukemia (AML). Our lead candidate, mipletamig, is a CD3 x CD123 bispecific antibody designed to engage the immune system and target AML cells with precision. With promising early data, mipletamig has the potential to bring new hope to patients and their families. Together, we’re pushing the boundaries of cancer care and aiming for better outcomes for those who need it most. #AptevoTherapeutics #Mipletamig #AML #Oncology #CancerResearch #Biotech

At Aptevo Therapeutics, we are committed to developing innovative solutions for patients battling acute myeloid leukemia (AML). Our lead candidate, mipletamig, is a CD3 x CD123 bispecific antibody designed to engage the immune system and target AML cells with precision. With promising early data, mipletamig has the potential to bring new hope to patients and their families. Together, we’re pushing the boundaries of cancer care and aiming for better outcomes for those who need it most. #AptevoTherapeutics #Mipletamig #AML #Oncology #CancerResearch #Biotech

Excited to share that KPMG's Alumni on the Rise series featured Akmal Abdulmuminov, our talented, dedicated all around "great guy" and director of finance. Congratulations Akmal. We are lucky to have you as a leader on our team!

Breaking: Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study.

A warm congratulations and wishes for all the best to Aptevo board member, Barbara Lopez Kunz, who has been appointed CEO of Caidya.